The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 345:292-293 July 26, 2001 Number 4
NextNext

Low-Molecular-Weight Heparin in Patients with Deep-Vein Thrombosis

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
To the Editor: The clinical importance of rapidly achieving a therapeutic activated partial-thromboplastin time with respect to the treatment of venous thromboembolism with unfractionated heparin has been underscored in various studies1 and reviews.2 Breddin et al. (March 1 issue)3 compared intravenous unfractionated heparin with subcutaneous weight-adjusted reviparin, given once or twice a day, as a therapy for deep-vein thrombosis. Reviparin (a low-molecular-weight heparin) was more effective than unfractionated heparin in reducing the size of the thrombus, and twice-daily administration of reviparin prevented recurrent thromboembolism better than did treatment with unfractionated heparin. The patients received fixed initial doses of unfractionated heparin, . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.